Mon Sep 23 23:10:00 UTC 2024: ## Regen BioPharma to Present at Emerging Growth Conference
**SAN DIEGO, CA – September 23, 2024** – Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP), a biotechnology company developing innovative therapies for cancer and autoimmune diseases, will present at the Emerging Growth Conference on September 25th, 2024.
The live, interactive online presentation will offer investors and the public the chance to engage with Regen BioPharma’s CEO, Dr. David Koos, and gain insights into the company’s progress. The presentation will focus on the company’s fiscal and scientific goals for the coming year, updates on current programs, and the timeline for its anticipated HemaXellerate clinical phase I trial.
“We are excited to use this platform to share our progress with investors,” said Dr. Koos. “This event will provide valuable insights into our commitment to developing cutting-edge therapies.”
The presentation will take place from 4:00 pm to 4:10 pm Eastern time on Wednesday, September 25th. Interested attendees can register for the conference and access archived webcasts on EmergingGrowth.com.
The Emerging Growth Conference provides a platform for public companies to showcase their innovative products, services, and announcements to a large audience of investors, advisors, and analysts. It features companies from various growth sectors with strong management teams and innovative products and services.
Regen BioPharma, Inc. is a publicly traded biotechnology company focused on developing innovative therapies for cancer and autoimmune disorders. The company is currently focusing on mRNA and small molecule therapies to address these conditions.
**To learn more about Regen BioPharma, Inc., visit their website at http://www.regenbiopharmainc.com.**
First Piper 